Rosenblum M L, Dougherty D A, Deen D F, Hoshino T, Wilson C B
Br J Cancer Suppl. 1980 Apr;4:181-5.
Biopsies from 6 patients with glioblastoma multiforme were disaggregated and single cells were treated in vitro with various concentrations of BCNU and plated for cell survival. One patient's cells were sensitive to BCNU in vitro; after a single dose of BCNU her brain scan reverted to normal and she was clinically well. Five tumours demonstrated resistance in vitro. Three of these tumours progressed during the first course of chemotherapy with a nitrosourea and the patients died at 2 1/2, 4 and 8 1/2 months after operation. Two patients who showed dramatic responses to radiation therapy were considered unchanged after the first course of nitrosourea therapy (although one demonstrated tumour enlargement on brain scan). The correlation of in vitro testing of tumour cell sensitivity with actual patient response is encouraging enough to warrant further work to determine whether such tests should weigh in decisions on patient therapy.
对6例多形性胶质母细胞瘤患者的活检组织进行解离,将单个细胞用不同浓度的卡莫司汀(BCNU)进行体外处理,然后接种以检测细胞存活率。1例患者的细胞在体外对BCNU敏感;单次给予BCNU后,她的脑部扫描恢复正常,临床状况良好。5个肿瘤在体外表现出耐药性。其中3个肿瘤在使用亚硝基脲进行的首个化疗疗程中进展,患者分别在术后2.5个月、4个月和8.5个月死亡。2例对放射治疗有显著反应的患者在首个亚硝基脲治疗疗程后被认为病情未变(尽管其中1例脑部扫描显示肿瘤增大)。肿瘤细胞敏感性的体外检测结果与实际患者反应之间的相关性令人鼓舞,足以保证进一步开展工作,以确定此类检测是否应在患者治疗决策中发挥作用。